Renal Cell Carcinoma Highlights From ASCO GU 2024 Renal Cell Carcinoma Highlights From ASCO GU 2024
Key data in renal cell carcinoma from ASCO GU 2024 includes pembrolizumab in early higher-risk RCC, belzutifan in advanced disease, and developments in quality-of-life tools.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 16, 2024 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Advancements in RCC Treatment and Cure Rates Advancements in RCC Treatment and Cure Rates
Dr Katy Beckermann expresses optimism for the future of the treatment of renal cell carcinoma through the safe combination of new therapeutic agents.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 16, 2024 Category: Consumer Health News Tags: None MDAngle Source Type: news

Miracle drug that stops killer kidney cancer from coming back to be offered to 80 per cent of NHS patients with the disease
The injection, pembrolizumab, looks set to become the standard treatment given to patients after surgery after a trial saw survival rates soar. (Source: the Mail online | Health)
Source: the Mail online | Health - February 4, 2024 Category: Consumer Health News Source Type: news

Sheriff, 62, from Louisiana claims sleep apnea mask he used for four years gave him KIDNEY CANCER - as FDA reveals nearly 600 deaths linked to Philips' CPAP devices
The Food and Drug Administration reported that since initiating a massive recall of CPAP machines in 2021, 561 Americans have died as a result of illnesses linked to the faulty machines. (Source: the Mail online | Health)
Source: the Mail online | Health - February 1, 2024 Category: Consumer Health News Source Type: news

' Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer
KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
WEDNESDAY, Jan. 31, 2024 -- For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2024 Category: Pharmaceuticals Source Type: news

Injected Opdivo for Kidney Cancer Works Equally Well as IV Form: Study
TUESDAY, Jan. 30, 2024 -- Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current method of intravenous delivery, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 30, 2024 Category: General Medicine Source Type: news

Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma -- With Much Faster Treatment Time
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park Comprehensive Cancer Center today at the 2024... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings. Patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news

Telix submits PET tracer for FDA review
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its clear cell renal cell carcinoma PET radiotracer TLX250-CDx (Zircaix).The PET tracer has been granted a rolling review process under the FDA’s Breakthrough Therapy designation, which will enable a progressive submission and review of required modules in a timeframe agreed upon with the FDA, the company said. It has also requested priority review.In addition, Telix said it has opened an expanded access program in the U.S. and a named-patient program in Europe to allow access to Zircaix outside of...
Source: AuntMinnie.com Headlines - December 19, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Belzutifan Approved for Advanced Renal Cell Carcinoma Belzutifan Approved for Advanced Renal Cell Carcinoma
The FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
(MedPage Today) -- The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday. Belzutifan is indicated for RCC patients with disease progression after a PD-1/L1 checkpoint... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 15, 2023 Category: American Health Source Type: news

FDA Approves Merck ’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news

FDA approves belzutifan for advanced renal cell carcinoma
On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck& Co., Inc.) for patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Metastatic Kidney Cancer Highlights From IKCS 2023 Metastatic Kidney Cancer Highlights From IKCS 2023
Highlights on metastatic kidney cancer research from IKCS 2023 include data on zanzalintinib, a dose-finding study on belzutifan, and updates on CAR T-cell therapy, as reported by Dr Brian Rini.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news